Hyperhomocysteinaemia Promotes Doxorubicin-Induced Cardiotoxicity in Mice
Doxorubicin, a widely used chemotherapeutic drug in clinical oncology, causes a series of cardiac side effects referred to as doxorubicin-induced cardiotoxicity. Hyperhomocysteinaemia is an independent risk factor for multiple cardiovascular diseases. However, whether hyperhomocysteinaemia contribut...
Saved in:
Main Authors: | Rui Fan (Author), Yao Wang (Author), Jinjin Zhang (Author), Xiangbo An (Author), Shuang Liu (Author), Jie Bai (Author), Jiatian Li (Author), Qiuyue Lin (Author), Yunpeng Xie (Author), Jiawei Liao (Author), Yunlong Xia (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacological senolysis reduces doxorubicin-induced cardiotoxicity and improves cardiac function in mice
by: Araceli Lérida-Viso, et al.
Published: (2022) -
Fluorouracil and doxorubicin - cardiotoxic cytostatics in the workplace
by: Małgorzata Kupczewska-Dobecka, et al.
Published: (2020) -
Cardiotoxicity of doxorubicin - causes, prevention, prospects
by: Paweł Wesołowski, et al.
Published: (2022) -
Protection against Doxorubicin-Induced Cardiotoxicity by Ergothioneine
by: Irwin K. Cheah, et al.
Published: (2023) -
Bibliometric and visual analysis of doxorubicin-induced cardiotoxicity
by: Xiaoxiao Lin, et al.
Published: (2023)